Merck has inaugurated a new medical packaging facility in Aubonne, Switzerland for biotechnological medicines. USA based biotechnological medicine company – Merck – has had a biotech manufacturing site in Aubonne since 1984. The new packaging facility took 18 months and will allow shipment to 150 countries where Merck operates. According to Stefano Induni from Merck, the new building is designed to accompany the growth of the company’s business with special connection to the launch of anti-cancer drug (skin and bladder) named Bavencio. For oncology, fertility or endocrinology, each year 12 million boxes of drugs and 4 million auto injectors will be produced and shipped globally.
The main building, with 8,000 meters square area, will be used for inspection, packaging and distribution while other parts of the building will be used for cancer immunotherapy. Merck has 2,000 employees and 11 sites in Switzerland while the Aubonne site itself employs more than 700 employees. Merck over the years has invested one billion Swiss Francs in Switzerland. According to Stefan Oschmann, CEO and Chairman of the Merck Executive Board, Switzerland is a prime hub for manufacturing of biotech medicines for patients all over the world.
Merck has a history of 125 years and since 1891 Merck has been credited to the discovery of vitamin B1, made the first measles vaccine, produced one of the first cold remedies and antacids, and made the first statins to treat high cholesterol and various vaccines and antibiotics. Recently Merck has also helped develop products for animal health. Merck is known as MSD everywhere else expect United States and Canada where it is known as Merck. One of the largest pharmaceuticals in the world Merck employs around 68,000 people worldwide as of 12/31/16.